20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Pulmonary arterial hypertension in patients treated by dasatinib.

      Circulation
      Adolescent, Adult, Adverse Drug Reaction Reporting Systems, Aged, Antineoplastic Agents, adverse effects, pharmacology, therapeutic use, Benzamides, Bone Morphogenetic Protein Receptors, Type II, genetics, Calcium Channel Blockers, Drug Utilization, statistics & numerical data, Endothelin Receptor Antagonists, Female, Follow-Up Studies, Hemodynamics, drug effects, Humans, Hydroxyurea, Hypertension, Pulmonary, chemically induced, diagnosis, drug therapy, epidemiology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Middle Aged, Piperazines, Protein Kinase Inhibitors, Pyrimidines, Registries, Thiazoles, Treatment Outcome

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The French pulmonary hypertension (PH) registry allows the survey of epidemiological trends. Isolated cases of precapillary PH have been reported in patients who have chronic myelogenous leukemia treated with the tyrosine kinase inhibitor dasatinib. This study was designed to describe incident cases of dasatinib-associated PH reported in the French PH registry. From the approval of dasatinib (November 2006) to September 30, 2010, 9 incident cases treated by dasatinib at the time of PH diagnosis were identified. At diagnosis, patients had moderate to severe precapillary PH with functional and hemodynamic impairment. No other incident PH cases were exposed to other tyrosine kinase inhibitors at the time of PH diagnosis. Clinical, functional, or hemodynamic improvements were observed within 4 months of dasatinib discontinuation in all but 1 patient. Three patients required PH treatment with endothelin receptor antagonist (n=2) or calcium channel blocker (n=1). After a median follow-up of 9 months (min-max 3-36), the majority of patients did not demonstrate complete clinical and hemodynamic recovery, and no patients reached a normal value of mean pulmonary artery pressure (≤20 mm Hg). Two patients (22%) died at follow-up (1 of unexplained sudden death and 1 of cardiac failure in the context of septicemia, respectively, 8 and 12 months after dasatinib withdrawal). The lowest estimate of incident PH occurring in patients exposed to dasatinib in France was 0.45%. Dasatinib may induce severe precapillary PH fulfilling the criteria of pulmonary arterial hypertension, thus suggesting a direct and specific effect of dasatinib on pulmonary vessels. Improvement is usually observed after withdrawal of dasatinib.

          Related collections

          Author and article information

          Comments

          Comment on this article

          scite_

          Similar content712

          Cited by145